BCAX Bicara Therapeutics Inc.

NEUTRAL Impact: 2/10 PRESS-RELEASE
Horizon days Filed Apr 3, 2026 Processed 2mo ago Wire GlobeNewswire
Press release: contract
Latest settled — T+20d
BCAX ▲ +8.97% at T+20d
NEUTRAL call ✓ call won +8.97% · α vs SPY -0.01% · entry $20.85 → $22.72
Next anchor: T+60d in 20d
Currently $20.56 · -1.39% from $20.85 entry
Entry anchored
Apr 2, 03:59 PM ET
via Databento tick
T+1d
+2.11%
call +2.11% · α +2.05%
$21.29
settled 2mo ago
T+5d
+6.19%
call +6.19% · α +2.05%
$22.14
settled 2mo ago
T+20d
+8.97%
call +8.97% · α -0.01%
$22.72
settled 6w ago
T+60d
call — · α —
in 20d

Price Chart

Loading chart...

Executive Summary

Bicara Therapeutics granted a stock option to purchase 44,175 shares to a new employee as an inducement to join the company. The award was made outside of its shareholder-approved plans under the 2026 Inducement Plan, consistent with Nasdaq rules.

Actionable Insight

Monitor for additional inducement grants or insider activity; this isolated grant is routine for biotech firms and unlikely to move the stock. However, recent insider selling of $305K over 30 days may signal caution.

Key Facts

  • Bicara Therapeutics granted a non-qualified stock option to purchase 44,175 shares to a new employee on April 1, 2026.
  • The option has an exercise price of $20.50 per share, equal to the closing price on the grant date.
  • Vesting: 25% on first anniversary, remaining 75% over 12 equal quarterly installments.
  • Grant made under the 2026 Inducement Plan, approved by independent directors, outside shareholder-approved equity plans.
  • No financial metrics, revenue, or earnings impact disclosed.

Financial Impact

Minimal near-term financial impact; potential for minor dilution from 44,175 shares.

dilutionshare_count

Risk Factors

  • Potential for incremental dilution if multiple such grants occur.
  • Insider selling trend may contrast with positive messaging around hiring.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3267999
12 reports for BCAX
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for BCAX — sortable, filterable
Type Now
May 26, 2026
14d ago
Insider Cluster
NEUTRAL ★ 2/10
$21.58 $20.00▼ −7.32%▼ −7.79%$20.56 (−4.73%)
May 11, 2026
29d ago
8-K
NEUTRAL ★ 4/10
$22.92 $19.29▼ −15.84%▼ −15.75%$20.56 (−10.30%)
May 4, 2026
5w ago
Press Release
NEUTRAL ★ 2/10
$22.72 $22.92▲ +0.88%▼ −2.06%$20.56 (−9.51%)
Apr 27, 2026
6w ago
DEFA14A
NEUTRAL ★ 2/10
$22.48 $22.72▲ +1.09%▲ +0.69%$20.56 (−8.52%)
Apr 20, 2026
7w ago
Insider Cluster
NEUTRAL ★ 2/10
$21.28 $23.78▲ +11.75%▲ +8.64%$20.56 (−3.38%)
Apr 15, 2026
8w ago
Insider Cluster
NEUTRAL ★ 5/10
$23.72 $23.63▼ −0.38%▼ −2.02%$20.56 (−13.32%)
Apr 15, 2026
8w ago
Insider Cluster
BEARISH ★ 7/10
$23.72 $23.63▲ +0.38%▲ +2.02%$20.56 (+13.32%)
Apr 3, 2026
9w ago
Press Release
NEUTRAL ★ 2/10
$20.85 $22.14▲ +6.19%▲ +2.05%$20.56 (−1.39%)
Mar 23, 2026
11w ago
Press Release
NEUTRAL ★ 3/10
$18.39 $19.04▲ +3.53%▲ +7.10%$20.56 (+11.80%)
Mar 16, 2026
12w ago
Insider Cluster
NEUTRAL ★ 4/10
$19.40 $18.39▼ −5.21%▼ −3.16%$20.56 (+5.98%)
Showing 10 of 12

US Market Status

Market Closed — Opens Thu (9h 48m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access